The recommended dosage is not the deciding factor when classifying a product as a dietary supplement or as a medicinal product, Germany’s Supreme Court rules as product characteristics such as its health risks must be considered.
The highest European Court has for the first time expressed a legal position on the commercialisation of cannabidiol (CBD)-based products in Europe as its Advocate General said EU member states cannot ban the import of this ingredient.
